Moderna said on Monday it expects to report around $1.9  billion in sales for 2025, putting it near the upper end of its ...

SAN FRANCISCO — Despite all the hopeful chatter about the life sciences industry making a rebound after a multiyear ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

At the 44 th Annual JP Morgan Healthcare Conference on Monday, Moderna Inc. (NASDAQ:MRNA) said that it expects to report ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are ...

Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...

Moderna said it expects 2025 revenue of approximately $1.9 billion, which is $100 million above the midpoint previously ...

Moderna Inc. said its US Covid business did better than expected last year, a rare bright spot for the vaccine maker, which ...

The politicization of science is undermining the scientific method itself, the co-founder of the biotech firm Moderna warned.

Dr Melanie Ivarsson was on Monday named chief executive of the Health Data Research Service (HDRS), which will give ...